Equitec Specialists Has Lowered T Mobile Us (Put) (TMUS) Holding By $524,600; Last Week Merrimack Pharmaceuticals, Inc. (MACK) Analysts

March 14, 2018 - By Kurt Siggers

Equitec Specialists Llc decreased T Mobile Us Inc (Put) (TMUS) stake by 81.13% reported in 2017Q3 SEC filing. Equitec Specialists Llc sold 8,600 shares as T Mobile Us Inc (Put) (TMUS)’s stock rose 3.83%. The Equitec Specialists Llc holds 2,000 shares with $123,000 value, down from 10,600 last quarter. T Mobile Us Inc (Put) now has $55.52 billion valuation. The stock increased 0.67% or $0.43 during the last trading session, reaching $64.98. About 4.42M shares traded or 13.09% up from the average. T-Mobile US, Inc. (NYSE:TMUS) has risen 62.63% since March 14, 2017 and is uptrending. It has outperformed by 45.93% the S&P500.

Among 5 analysts covering Merrimack Pharmaceuticals (NASDAQ:MACK), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Merrimack Pharmaceuticals had 10 analyst reports since August 12, 2015 according to SRatingsIntel. Robert W. Baird maintained Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) on Monday, September 11 with “Hold” rating. The firm has “Outperform” rating given on Wednesday, August 12 by Oppenheimer. Robert W. Baird maintained the shares of MACK in report on Friday, October 13 with “Hold” rating. Oppenheimer maintained Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) on Tuesday, October 27 with “Outperform” rating. The firm has “Neutral” rating by Robert W. Baird given on Friday, May 27. JP Morgan downgraded Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) on Friday, October 7 to “Neutral” rating. BTIG Research initiated the shares of MACK in report on Friday, August 19 with “Neutral” rating. On Tuesday, August 11 the stock rating was maintained by Brean Capital with “Buy”. The firm has “Buy” rating by Mizuho given on Wednesday, December 23. The stock has “Outperform” rating by Mizuho on Wednesday, August 12. See Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) latest ratings:

13/10/2017 Broker: Robert W. Baird Rating: Hold New Target: $15.0 Maintain

Investors sentiment decreased to 1.04 in 2017 Q3. Its down 0.02, from 1.06 in 2017Q2. It dropped, as 62 investors sold TMUS shares while 161 reduced holdings. 67 funds opened positions while 169 raised stakes. 279.18 million shares or 0.29% more from 278.36 million shares in 2017Q2 were reported. Moreover, Gulf Intll Bancorporation (Uk) Ltd has 0.08% invested in T-Mobile US, Inc. (NASDAQ:TMUS). D Scott Neal, a Kentucky-based fund reported 411 shares. State Of Tennessee Treasury Department accumulated 732,700 shares or 0.23% of the stock. First Eagle Inv Mgmt Ltd Liability Corp accumulated 0% or 17,833 shares. Evercore Wealth Mngmt Ltd Limited Liability Company reported 8,563 shares stake. Gabelli Funds Ltd Co invested in 0.15% or 413,000 shares. The Belgium-based Kbc Nv has invested 0.13% in T-Mobile US, Inc. (NASDAQ:TMUS). Howe And Rusling reported 365 shares. 95,760 are owned by Paloma Prtn. Blackrock reported 15.98 million shares or 0.05% of all its holdings. California-based First Republic Inv Management Inc has invested 0.01% in T-Mobile US, Inc. (NASDAQ:TMUS). Prudential reported 25,060 shares. Daiwa Securities Gru Inc holds 0.01% or 14,900 shares. Aqr Cap Management Limited Liability Co has invested 0.01% in T-Mobile US, Inc. (NASDAQ:TMUS). Odey Asset Mgmt Gru Limited has invested 0% in T-Mobile US, Inc. (NASDAQ:TMUS).

Since February 14, 2018, it had 1 buy, and 0 selling transactions for $17.34 million activity. $17.34M worth of T-Mobile US, Inc. (NASDAQ:TMUS) was bought by Deutsche Telekom Holding B.V. on Wednesday, February 14.

Among 33 analysts covering T-Mobile US (NYSE:TMUS), 27 have Buy rating, 1 Sell and 5 Hold. Therefore 82% are positive. T-Mobile US had 78 analyst reports since August 3, 2015 according to SRatingsIntel. FBR Capital initiated the stock with “Market Perform” rating in Thursday, March 24 report. The rating was maintained by Buckingham Research on Thursday, August 25 with “Buy”. William Blair maintained T-Mobile US, Inc. (NASDAQ:TMUS) on Wednesday, April 26 with “Buy” rating. The stock has “Outperform” rating by Wells Fargo on Monday, August 29. The firm earned “Hold” rating on Wednesday, April 26 by Nomura. Pacific Crest maintained the stock with “Positive” rating in Wednesday, August 19 report. The rating was maintained by Canaccord Genuity with “Buy” on Friday, July 31. The rating was maintained by Bank of America with “Underperform” on Tuesday, October 24. Jefferies maintained T-Mobile US, Inc. (NASDAQ:TMUS) on Tuesday, August 1 with “Buy” rating. RBC Capital Markets maintained the shares of TMUS in report on Thursday, June 1 with “Buy” rating.

Equitec Specialists Llc increased Epr Pptys (Put) (NYSE:EPR) stake by 77,400 shares to 86,300 valued at $6.02M in 2017Q3. It also upped General Mtrs Co stake by 241,290 shares and now owns 387,645 shares. Verisign Inc (Prn) was raised too.

Analysts await T-Mobile US, Inc. (NASDAQ:TMUS) to report earnings on April, 23. They expect $0.75 EPS, up 63.04% or $0.29 from last year’s $0.46 per share. TMUS’s profit will be $640.82 million for 21.66 P/E if the $0.75 EPS becomes a reality. After $0.48 actual EPS reported by T-Mobile US, Inc. for the previous quarter, Wall Street now forecasts 56.25% EPS growth.

Investors sentiment is 0 in Q3 2017. Its the same as in 2017Q2. It has no change, as 101 investors sold Merrimack Pharmaceuticals, Inc. shares while 1 reduced holdings. only 0 funds opened positions while 0 raised stakes. 2.91 million shares or 95.42% less from 63.69 million shares in 2017Q2 were reported. Horrell Capital Management Inc owns 50 shares or 0% of their US portfolio. 27,500 are owned by Dekabank Deutsche Girozentrale. 10,539 are owned by Ameritas Investment Prtn. 2.88 million are owned by Putnam Invests Ltd.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company has market cap of $136.32 million. The company's therapeutic oncology candidates in clinical development include MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer; and MM-141 that is in Phase II clinical trial for treating previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1. It has a 0.3 P/E ratio. The Company’s therapeutic oncology candidates also comprise MM-310 for treating solid tumors; and MM-151 that has completed a Phase I clinical trial for treating solid tumors.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: